Trial Profile
Sargramostim to Reverse Myeloid Dendritic Cell Deficiency
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Sargramostim (Primary)
- Indications Acute radiation syndrome; Alzheimer's disease; Bone marrow disorders; Chronic lymphocytic leukaemia; Neutropenia; Pneumococcal infections; Prostate cancer; Pulmonary alveolar proteinosis; Stem cell mobilisation
- Focus Pharmacodynamics
- 21 Sep 2018 Status hs been changed to discontinued.
- 18 Sep 2018 Status changed from recruiting to completed.
- 20 Oct 2017 Planned number of patients changed from 15 to 25.